Lingertat-Walsh Karen, Law Shirley, Walker Scott E
, BScPhm, ACPR, is a Compounding Pharmacist with the Department of Pharmacy, The Hospital For Sick Children, Toronto, Ontario.
, DipPharmTech, is a Research Assistant in Quality Control, Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Ontario.
Can J Hosp Pharm. 2018 May-Jun;71(3):165-172. Epub 2018 Jun 28.
Domperidone liquid for oral administration is not commercially available in Canada, but is needed for patients who cannot swallow intact tablets.
To evaluate the stability of domperidone 5 mg/mL suspensions prepared in Oral Mix vehicle and stored, for up to 91 days, in amber polyvinylchloride (PVC) bottles, amber glass bottles, or amber polyethylene terephthalate (PET) bottles at 4°C or 25°C or in polypropylene oral syringes at 25°C.
Three separate 300-mL batches of domperidone suspension 5 mg/mL were prepared with Oral Mix vehicle. Fifty-millilitre aliquots of the suspension were stored in 100-mL bottles (amber PVC, amber glass, or amber PET). Half of the bottles of each type were stored at 25°C and half at 4°C. On study days 0, 1, 2, 4, 7, 10, 14, 21, 28, 35, 42, 49, 63, 77, and 91, domperidone concentration was determined, with a validated reverse-phase, stability-indicating liquid chromatographic method, in samples drawn from each type of container stored at each temperature. In addition, 1.5-mL aliquots of a fourth 100-mL batch of suspension were stored in 3-mL oral syringes at 25°C and were tested on the same study days.
The concentration of domperidone in all study samples remained above 93% of initial concentration after storage for 91 days. The percent remaining on day 91, based on fastest degradation rate (as represented by the lower limit of the 95% confidence interval [CI]), was at least 92.3% for suspensions stored at 4°C in PVC, glass, and PET bottles. With storage at 25°C, suspensions in PVC and glass bottles retained more than 90% of initial concentration, whereas suspensions in PET bottles and plastic syringes retained 88.9% and 88.0% of initial concentration, respectively.
Because suspensions of domperidone in PET bottles and oral syringes retained less than 90% of their initial concentration on day 91 (based on the 95% CI), it is suggested that such suspensions be stored at 4°C or 25°C in any bottle type or syringe with an assigned beyond-use date not exceeding 75 days.
加拿大市面上没有可供口服的多潘立酮液体制剂,但无法吞咽完整片剂的患者需要这种制剂。
评估用口服混合赋形剂配制的5毫克/毫升多潘立酮混悬液在4℃或25℃下,于琥珀色聚氯乙烯(PVC)瓶、琥珀色玻璃瓶或琥珀色聚对苯二甲酸乙二酯(PET)瓶中,或在25℃下于聚丙烯口服注射器中储存长达91天的稳定性。
用口服混合赋形剂制备三批独立的300毫升5毫克/毫升多潘立酮混悬液。将50毫升混悬液等分试样储存在100毫升瓶(琥珀色PVC瓶、琥珀色玻璃瓶或琥珀色PET瓶)中。每种类型的瓶子一半储存在25℃,一半储存在4℃。在研究第0、1、2、4、7、10、14、21、28、35、42、49、63、77和91天,采用经过验证的反相、稳定性指示液相色谱法,测定从每种类型容器中取出并储存在每个温度下的样品中的多潘立酮浓度。此外,将第四批100毫升混悬液的1.5毫升等分试样储存在25℃的3毫升口服注射器中,并在相同研究日进行检测。
所有研究样品中的多潘立酮浓度在储存91天后仍保持在初始浓度的93%以上。根据最快降解率(以95%置信区间[CI]下限表示),在4℃下储存在PVC瓶、玻璃瓶和PET瓶中的混悬液在第91天剩余的百分比至少为92.3%。在25℃储存时,PVC瓶和玻璃瓶中的混悬液保留了超过90%的初始浓度,而PET瓶和塑料注射器中的混悬液分别保留了88.9%和88.0%的初始浓度。
由于多潘立酮在PET瓶和口服注射器中的混悬液在第91天保留的初始浓度低于90%(基于95%CI),建议此类混悬液在4℃或25℃下储存在任何类型的瓶子或注射器中,指定的使用期限不超过75天。